Although both drugs were extensively studied before approval, semaglutide has only been on the market since 2017 and tirzepatide since 2022
3 Beyond weight loss, the highest dose delivered meaningful reductions in cardiovascular risk factors: triglycerides fell by an average of 37.0%, non-HDL cholesterol by 16.5%, systolic blood pressure by 9.3 mmHg, waist circumference by 7.5 inches and high-sensitivity C-reactive protein by 51.2%
The truth is more nuanced: GLP-1 medications can be part of a long-term care plan, but ongoing success depends on understanding how appetite, metabolism, and daily habits work together
Approximately 66 million adults in Europe currently live with diabetes, representing a substantial patient population for GLP-1 therapies
Lancet 396 , 819829 (2020)